Organization, Business, Basis of Presentation and Summary of Significant Accounting Policies - Summary of Significant Expense Categories Reviewed By CODM (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
Jun. 30, 2026 |
Mar. 31, 2026 |
Jun. 30, 2025 |
Mar. 31, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| Research and development expenses: | ||||||
| Efzofitimod expenses | $ 2,106 | $ 12,290 | $ 5,641 | $ 21,094 | ||
| Preclinical development and other shared research and development expenses | 4,230 | 2,623 | 7,585 | 5,184 | ||
| Non-cash expenses (depreciation and stock-based compensation) | 412 | 471 | 839 | 920 | ||
| Total research and development expenses | 6,748 | 15,384 | 14,065 | 27,198 | ||
| General and administrative expenses: | ||||||
| Other general and administrative expenses | 3,232 | 3,928 | 6,307 | 6,992 | ||
| Non-cash expenses (depreciation and stock-based compensation) | 901 | 1,001 | 1,945 | 1,896 | ||
| Total general and administrative expenses | 4,133 | 4,929 | 8,252 | 8,888 | ||
| Other segment items | 571 | 781 | 1,215 | 1,673 | ||
| Consolidated net loss | $ (10,310) | $ (10,792) | $ (19,532) | $ (14,881) | $ (21,102) | $ (34,413) |
| X | ||||||||||
- Definition Efzofitimod research and development expenses. No definition available.
|
| X | ||||||||||
- Definition Non-cash expenses related to general and administrative expenses. No definition available.
|
| X | ||||||||||
- Definition Non-cash research and development expenses. No definition available.
|
| X | ||||||||||
- Definition Preclinical Development And Other Shared Research And Development Expense No definition available.
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of general and administrative expense classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss). Reference 1: http://www.xbrl.org/2003/role/exampleRef
|